{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:04:11Z","timestamp":1790935451291,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The objective of this study was to compare efficacy and safety of continuous versus intermittent oral dosing of ibandronate. Two hundred forty women aged 55\u201375 years with postmenopausal osteoporosis were randomized to active treatment or placebo. Similar total doses of ibandronate were provided by treatment regimens with either continuous 2.5 mg of ibandronate daily (n = 81) or intermittent 20 mg of ibandronate every other day for the first 24 days, followed by 9 weeks without active drug (n = 78). The placebo group (total, n = 81) was crossed over after 12 months to receive either continuous (n = 37) or intermittent ibandronate (n = 35). By 24 months, bone mineral density (BMD) had increased significantly relative to baseline in both active treatment groups. The continuous and intermittent groups showed statistically equivalent increases in lumbar spine BMD of +5.64% (\u00b10.53) and +5.54% (\u00b10.53) and in total hip of +3.35% (\u00b10.40) and +3.41% (\u00b10.40), respectively (per protocol population). Biochemical markers of bone turnover decreased significantly in both treatment groups. The level of marker suppression was similar, although the intermittent group displayed, as expected, more fluctuation over the treatment period. The frequency of adverse events was similar in the treatment groups. In conclusion, the intermittent and continuous regimens showed equivalent changes in BMD and bone turnover. These results confirm previous preclinical findings indicating that the efficacy of ibandronate depends on the total oral dose given rather than on the dosing schedule. This supports development of new flexible dosing regimens targeted to minimize the frequency of dosing, which are expected to improve convenience and lead to enhanced long-term patient compliance.<\/jats:p>","DOI":"10.1359\/jbmr.2001.16.10.1871","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T03:14:25Z","timestamp":1146107665000},"page":"1871-1878","source":"Crossref","is-referenced-by-count":83,"title":["Ibandronate: A Comparison of Oral Daily Dosing Versus Intermittent Dosing in Postmenopausal Osteoporosis"],"prefix":"10.1093","volume":"16","author":[{"given":"B. J.","family":"Riis","sequence":"first","affiliation":[{"name":"Bente Riis is a research physician at the Center for Clinical and Basic Research and served as an ad hoc consultant for Besins EscoVesco, Boehringer Mannheim, Chiesi, Croupe Fournier Roche, Eli Lilly, MSD, Novo Nordisk, Pfizer, Proctor and Gamble, Sandoz (now Novartis), and Wyeth-Ayerst. Dr. Riis also is the founder of Osteometer Biotech A\/S"},{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ise","sequence":"additional","affiliation":[{"name":"J\u00fcergen Ise is an employee of Roche Diagnostics"},{"name":"Roche Global Development, Mannheim, Germany, and Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Von Stein","sequence":"additional","affiliation":[{"name":"Thorsten von Stein is an employee of Roche Diagnostics"},{"name":"Roche Global Development, Mannheim, Germany, and Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Bagger","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Claus Christiansen is the CEO of the Center for Clinical and Basic Research and served as an ad hoc consultant for Besins EscoVesco, Boehringer Mannheim, Chiesi, Croupe Fournier Roche, Eli Lilly, MSD, Novo Nordisk, Pfizer, Procter and Gamble, Sandoz (now Novartis), and Wyeth-Ayerst. Dr. Christiansen also is the founder and board member of Osteometer Biotech A\/S"},{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020714121037400_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: From the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"2024020714121037400_bib2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib3","first-page":"S1;S336","article-title":"Comparison of continuous and cyclical administration of ibandronate on bone mass in ovariectomized rats","volume":"11","author":"Bauss","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib4","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib5","first-page":"S1;S402","article-title":"Effects of ibandronate treatment on bone mass, architecture and strength in the ovariectomized cynomolgus monkey","volume":"14","author":"Smith","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"2024020714121037400_bib7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/clinchem\/41.10.1439","article-title":"Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies","volume":"41","author":"Rosenquist","year":"1995","journal-title":"Clin Chem"},{"key":"2024020714121037400_bib8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/clinchem\/39.4.648","article-title":"Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma","volume":"39","author":"Rosalki","year":"1993","journal-title":"Clin Chem"},{"key":"2024020714121037400_bib9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1359\/jbmr.1997.12.7.1028","article-title":"Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen","volume":"12","author":"Bonde","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/jbmr.5650071119","article-title":"A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine","volume":"7","author":"Hanson","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020714121037400_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: Preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Ann Med"},{"key":"2024020714121037400_bib12","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care"},{"key":"2024020714121037400_bib13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"35","author":"De Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"2024020714121037400_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S8756-3282(98)00044-1","article-title":"Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment","volume":"22","author":"Ravn","year":"1998","journal-title":"Bone"},{"key":"2024020714121037400_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S8756-3282(00)00291-X","article-title":"Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis","volume":"27","author":"Rossini","year":"2000","journal-title":"Bone"},{"key":"2024020714121037400_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone."},{"key":"2024020714121037400_bib17","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","article-title":"Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial","volume":"157","author":"Ensrud","year":"1997","journal-title":"Arch Intern Med"},{"key":"2024020714121037400_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"2024020714121037400_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"2024020714121037400_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pharmtox.38.1.375","article-title":"Mechanism of action of bisphosphonates","volume":"38","author":"Rodan","year":"1998","journal-title":"Ann Rev Pharmacol Toxicol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2001.16.10.1871","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/10\/1871\/56604863\/5650161018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/10\/1871\/56604863\/5650161018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:43Z","timestamp":1710342103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/16\/10\/1871-1878\/7515861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2001.16.10.1871","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,10,1]]},"published":{"date-parts":[[2001,10,1]]}}}